IL17A and rheumatoid arthritis: Another two trials on refractory RA patients explored the effects of autologous BM-MSCs and showed a decrease in the Th17 percentage and IL-17 levels, as well as a significant increase in Tregs and their cytokines, specifically IL-10 and TGF-β.